CIRM provides funding across five key areas: Infrastructure, Education, Discovery Research, Translational Research, and Clinical Research. By supporting projects at every stage of development, from initial discovery to clinical trials, CIRM drives progress in regenerative medicine and accelerates innovative therapies to patients.
Check out our portfolio of awards below. Click here to see a list of People We’ve Funded. Click here to see a list of our Funded Institutions.
All CIRM Grants
Search Filters »
| Institution |
Researcher name |
Grant Type |
Grant Title |
Award Value |
| Cedars-Sinai Medical Center |
Dr. Terrence Town |
Transplantation Immunology |
Role of HLA in neural stem cell rejection using humanized mice |
$1,119,385 |
| University of Southern California |
Dr. Terrence Christopher Town |
Transplantation Immunology |
Role of HLA in neural stem cell rejection using humanized mice |
$353,249 |
| Stanford University |
Professor Christopher H. Contag |
Transplantation Immunology |
Engineering Embryonic Stem Cell Allografts for Operational Tolerance |
$1,411,338 |
| University of California, San Diego |
Dr Yang Xu |
Transplantation Immunology |
Induction of immune tolerance to human embryonic stem cell-derived allografts |
$1,192,680 |
| University of California, Los Angeles |
UCLA Gay Miriam Crooks |
Transplantation Immunology |
Engineering Thymic Regeneration to Induce Tolerance |
$1,235,445 |
| University of California, Davis |
Dr. William J Murphy |
Transplantation Immunology |
Donor natural killer (NK) cells as “veto” cells to promote donor-specific tolerance |
$1,257,601 |
| Palo Alto Veterans Institute for Research |
Dr. Husein Hadeiba |
Transplantation Immunology |
Application of Tolerogenic Dendritic Cells for Hematopoietic Stem Cell Transplantation |
$733,061 |
| Escape Therapeutics, Inc |
Basil M Hantash |
Transplantation Immunology |
Development of an immune tolerant hESC source for allogeneic cell therapy applications |
$1,453,040 |
| La Jolla Institute for Allergy and Immunology |
Dr. Anjana Rao |
Transplantation Immunology |
Generation of regulatory T cells by reprogramming |
$1,464,446 |
| University of California, San Francisco |
Dr. Tippi C. MacKenzie |
Transplantation Immunology |
Maternal and Fetal Immune Responses to In Utero Hematopoietic Stem Cell Transplantation |
$1,230,869 |
| Scripps Research Institute |
Dr. Jeanne F Loring |
Transplantation Immunology |
Thymus based tolerance to stem cell therapies |
$1,108,921 |
| Stanford University |
Dr. Judith A Shizuru |
Transplantation Immunology |
Purified allogeneic hematopoietic stem cells as a platform for tolerance induction |
$1,233,275 |
| University of California, San Francisco |
Dr. Jeffrey A Bluestone |
Transplantation Immunology |
Stem cell tolerance through the use of engineered antigen-specific regulatory T cells |
$1,152,768 |
| University of California, San Francisco |
Dr. Mark S. Anderson |
Transplantation Immunology |
Stem cell differentiation to thymic epithelium for inducing tolerance to stem cells |
$1,314,089 |
| University of California, San Diego |
Dr. Ying Liu |
Tools and Technologies I |
Generation of disease models for neurodegenerative disorders in hESCs by gene targeting |
$709,829 |
| University of California, Davis |
Kit S Lam |
Tools and Technologies I |
Discovery of adhesion ligands for pluripotent human stem cells |
$834,003 |
| ViaCyte, Inc. |
Dr. Evert J. Kroon |
Tools and Technologies I |
Development of the Theracyte Cellular Encapsulation System for Delivery of human ES Cell-derived Pancreatic Islets and Progenitors. |
$827,072 |
| University of California, Irvine |
Dr. Lisa A Flanagan |
Tools and Technologies I |
Novel Separation of Stem Cell Subpopulations |
$861,122 |
| University of California, Berkeley |
Dr. Steven M. Conolly |
Tools and Technologies I |
Magnetic Particle Imaging: A Novel Ultra-sensitive Imaging Scanner
for Tracking Stem Cells In Vivo |
$858,345 |
| University of Southern California |
Dr. Pin Wang |
Tools and Technologies I |
Development of Baculoviral Vectors for Gene Editing of Human Stem Cells |
$945,604 |
| Gamma Medica-Ideas, Inc. |
Douglas Jay Wagenaar |
Tools and Technologies I |
A Novel SPECT Microscopy System for 3D Imaging of Single Stem Cells In Vivo |
$800,065 |
| University of California, Davis |
Dr. Alice F Tarantal |
Tools and Technologies I |
In Vivo Imaging for the Detection and Quantitation of Transplanted Stem/Progenitor Cells in Nonhuman Primates |
$799,350 |
| University of California, Merced |
Dr. Michael Cleary |
Tools and Technologies I |
RNA Analysis by Biosynthetic Tagging (RABT): a tool for the identification of cell type-specific RNAs |
$481,096 |
| Stanford University |
Professor Helen M. Blau PhD |
Tools and Technologies I |
Regulation of Stem Cell Fate in Bioengineered Arrays of Hydrogel Microwells |
$949,608 |
| City of Hope, Beckman Research Institute |
Joseph D Gold |
Tools and Technologies I |
Development of Suspension Adaptation, Scale-up cGMP Banking and Cell Characterization Technologies for hESC Lines |
$882,929 |
| Vala Sciences, Inc. |
Patrick McDonough |
Tools and Technologies I |
Optimization in the Identification, Selection and Induction of Maturation of Subtypes of Cardiomyocytes derived from Human Embryonic Stem Cells |
$870,717 |
| University of California, Los Angeles |
Dr. Michael E. Phelps |
Tools and Technologies I |
Novel Tools and Technologies for Translational PET Imaging of Cell-based Therapies |
$914,039 |
| University of California, Irvine |
Dr. Orhan NALCIOGLU |
Tools and Technologies I |
A MULTI-MODALITY MOLECULAR IMAGING SYSTEM (MRSPECT) FOR IN VIVO STEM CELL TRACKING |
$719,798 |
| Scripps Research Institute |
Dr. Jeanne F Loring |
Tools and Technologies I |
The Stem Cell Matrix: a map of the molecular pathways that define pluripotent cells |
$1,133,552 |
| Scripps Research Institute |
Dr. Carlos F. Barbas Dr. |
Tools and Technologies I |
Development of a novel technology for precise, efficient, and safe genetic modification of stem cells |
$1,138,548 |
| University of California, Santa Cruz |
Dr. Joel Alan Kubby |
Tools and Technologies I |
AO Wide-Field Microscope |
$549,551 |
| University of California, San Diego |
Dr. Steven F Dowdy |
Tools and Technologies I |
TAT Cell-Permeable Protein Delivery of siRNAs for Epigenetic Programming of Human Pluripotent and Adult Stem Cells |
$720,000 |
| University of California, Santa Barbara |
Dr. Dennis O. Clegg |
Tools and Technologies I |
Synthetic Matrices for Stem Cell Growth and Differentiation |
$599,404 |
| Fluidigm Corporation |
Dr. Marc A Unger |
Tools and Technologies I |
Scaleup of Versatile, Fully Automated, Microfluidic Cell Culture System |
$749,518 |
| University of California, Los Angeles |
Dr. Hsian-Rong Tseng |
Tools and Technologies I |
Microfluidic Platform for Screening Chemically Defined Conditions that Facilitate Clonal Expansion of Human Pluripotent Stem Cells |
$914,096 |
| VistaGen Therapeutics, Inc. |
Dr. Kristina Bonham |
Tools and Technologies I |
Development of an hES Cell-Based Assay System for Hepatocyte Differentiation Studies and Predictive Toxicology Drug Screening |
$971,558 |
| University of California, Berkeley |
John Dueber |
Tools and Technologies I |
Directed Evolution of Novel AAV Variants for Enhanced Gene Targeting in Pluripotent Human Stem Cells and Investigation of Dopaminergic Neuron Differentiation |
$918,000 |
| Scribe Therapeutics |
Brett Staahl |
Preclinical Stage Projects |
A First-in-Class CIRSPR-CasX Gene Editing Therapy for Lowering Lp(a) to Prevent
Cardiovascular Events |
$12,714,480 |
| 4D Molecular Therapeutics, Inc. |
Dr Melissa Calton |
Preclinical Stage Projects |
Gene Therapy for Alpha-1 Anti-Trypsin Deficiency |
$5,915,073 |
| AcuraStem Incorporated |
Mr. Samuel V. Alworth MS, MBA |
Preclinical Stage Projects |
Late-stage development of AS-241, an UNC13A Targeting Antisense Oligonucleotide treatment for Amyotrophic Lateral Sclerosis, for IND-enabling studies |
$7,500,000 |
| Cure Rare Disease |
Dr. Tahseen Mozaffar |
Preclinical Stage Projects |
Advancement of a myotropic, liver-detargeting therapy for LGMD2i/R9 |
$7,292,297 |
| Scribe Therapeutics |
Brett Staahl |
Preclinical Stage Projects |
A first-in-class CRISPR-CasX gene editor silencing APOC3 transcription for the treatment of Severe Hypertriglyceridemia |
$13,000,000 |
| Savanna Biotherapeutics, Inc. |
Dr. Sunil Gandhi Ph.D |
Preclinical Stage Projects |
Microglia replacement therapy for CSF1R-related Leukoencephalopathy |
$12,993,456 |
| Cedars-Sinai Medical Center |
Dr. David Joseph Lefer |
Preclinical Stage Projects |
TY1 and Semaglutide to Treat Cardiometabolic HFpEF |
$10,571,220 |
| University of California, San Diego |
Dr. Stephanie Cherqui |
Preclinical Stage Projects |
CRISPR/Cas9-mediated gene editing of Hematopoietic stem and progenitor cells for Friedreich’s ataxia |
$7,423,504 |
| Cedars-Sinai Medical Center |
Dr. Alessandra Ciullo |
Preclinical Stage Projects |
Noncoding RNA drug TY2 for arrhythmogenic cardiomyopathy |
$10,419,929 |
| Navega Therapeutics |
Ana Maria Moreno |
Preclinical Stage Projects |
Development of an AAV Epigenetic Gene Therapy for Intractable Chronic Pain Disorders |
$9,486,864 |
| Scripps Health |
Dr. Darryl D. D’Lima |
Preclinical Stage Projects |
Stem Cell-Based Cartilage Tissue Regeneration |
$12,715,000 |
| Stanford University |
Dr. Bertha Chen |
Preclinical Stage Projects |
Autologous iPSC-derived progenitor smooth muscle cells for treatment of urinary incontinence |
$7,275,596 |
| Loma Linda University |
Hisham Abdel-Azim |
CCCE Grant |
Inland Empire and Desert Region CIRM Community Care Center of Excellence |
$9,000,000 |
